Category: Accuray Inc.Syndicate content

Accuray slides on lowered sales outlook

May 9, 2012 by MassDevice staff

Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year.

MassDevice.com news

Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.

The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.

MassDevice.com +3 | The top 3 med-tech stories for May 7, 2012.

May 7, 2012 by MassDevice staff

Accuray CEO Euan Thomson tells MassDevice.com what it means to have a robotic device, the SEC probes Baxter on infusion pump recalls and St. Jude Medical's largest backer boosts stake by 30%.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray CEO Euan Thomson: CyberKnife is the "true robotic system"

May 7, 2012 by Arezu Sarvestani

Accuray CEO Euan Thomson discusses the finer points of robotic prostate cancer treatment and the motivation behind a head-to-head clinical trial pitting its CyberKnife radiosurgery system against Intuitive Surgical's da Vinci.

Accuray CEO Euan Thomson

Prostate cancer: To cut or not to cut?

May 4, 2012 by MassDevice staff

Early results from a 10-year follow-up of prostate cancer treatment suggests that prostatectomy offers minimal survival benefits compared with the "wait and see" approach in certain patients.

surgery

Early results from a long-term study of prostate cancer patients concluded that removal of the gland barely increased the likelihood for survival in patients with low-risk tumors, concluding that the surgical approach "may be neither necessary nor effective."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +7 | The top 7 med-tech stories for the week of April 23, 2012.

April 27, 2012 by MassDevice staff

Boston Scientific warns on ICD electrical malfunctions in a pair of ICDs following 1 patient's death; device tax opposition forces seem to be gaining steam; HeartWare wins an FDA panel nod for its heart pump; analysts are cautious about Boston Scientific's $1.3B lead-free ICD ahead of an FDA panel; Accuray's CyberKnife plans to go head-to-head against Intuitive's da Vinci robot; a Senate panel adds safety measures to FDA's user fee act; and exposed FDA docs reveal misgivings about the EU's device review system.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

MassDevice.com +3 | The top 3 med-tech stories for April 26, 2012.

April 26, 2012 by MassDevice staff

HeartWare wins an FDA panel nod for its HVAD heart pump, Accuray's CyberKnife goes head-to-head against Intuitive's da Vinci robot and Zimmer slides on its Q1 results.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Accuray's CyberKnife goes head-to-head against Intuitive's da Vinci robot

April 26, 2012 by MassDevice staff

Accuray will go head-to-head against Intuitive Surgical in a first-of-its-kind clinical study comparing its CyberKnife radiosurgery system against the da Vinci surgical robot in efforts to establish a new gold standard for early-stage prostate cancer.

Accuray logo
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp